Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Asthma: full-pipeline trial registry
70 of 378 indexed Asthma trials are currently recruiting.
Corpus placement: #15 of 28,707 conditions by registered trial count.
378 US clinical trials · 70 currently recruiting · #15 of 28,707 conditions by registered trial count
Asthma: 378 US clinical trials tracked, 70 recruiting.
Asthma is the subject of 378 registered US clinical trials on ClinicalTrials.gov, 70 of them currently open to new participants. 89 are in Phase 3-4 (later-stage) and 108 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 24 of these trials.
Enrollment posture brief
Registry condition asthma
OPEN 70 | RECR 19% | LATE 89 | EARLY 108 | RANK #15 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Relapsing Remitting Multiple Sclerosis (19% recruiting · 27 trials)
Asthma lists 70 open slots (19% of 378 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Asthma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Asthma is recruiting below its size-band peers.
70 of 378 indexed trials (18.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Asthma trials is spread across many organizations.
GlaxoSmithKline accounts for 24 of 378 trials (6.3%). 161 distinct sponsors appear on at least one study for this condition label.
-
Typical Asthma enrolment sits around 144 participants.
Median target enrolment is 144 among the 375 trials that report a genuine target (sentinel values excluded). 160 of those (42.7%) plan for fewer than 100 participants.
-
Asthma research is mostly interventional.
298 interventional and 80 observational studies make up this index (78.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
378 total, page 3 of 8
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
Apogee Therapeutics
NCT06920901
Air Pollution, Asthma and Circadian Clocks
University of Pennsylvania
NCT03406351
Primary Care Implementation and Evaluation of Coach McLungs
Wake Forest University Health Sciences
NCT05059210
Probiotics and Insulin Resistance in Obese Asthmatics
University of Alabama at Birmingham
NCT05949255
How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice
Endeavor Health
NCT01979588
Replication of the D58 Asthma Trial in Healthcare Claims Data
Brigham and Women's Hospital
NCT04892732
Evaluation of VLER-Indiana Health Information Exchange Demonstration Project
VA Office of Research and Development
NCT01446705
Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children
Brigham and Women's Hospital
NCT00454415
The Breathe Well Program for Adults With Asthma
National Jewish Health
NCT02761837
Observational Study of Obstructive Lung Disease (NOVELTY)
AstraZeneca
NCT02760329
Environmental Polymorphisms Registry Health and Exposures Survey
National Institute of Environmental Health Sciences (NIEHS)
NCT01688986
Clinical Decision Support for Medication Management and Adherence
Duke University
NCT00979225
ParentLink: Better and Safer Emergency Care for Children
Boston Children's Hospital
NCT00457600
A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
Bond Avillion 2 Development
NCT05505734
A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
GlaxoSmithKline
NCT02924688
Asthma Exacerbation Study
GlaxoSmithKline
NCT01086384
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Sanofi
NCT02414854
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma
GlaxoSmithKline
NCT02301975
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
Chiesi Farmaceutici S.p.A.
NCT05292586
Telecommunication Enhanced Asthma Management
National Jewish Health
NCT00958932
Improving Asthma Outcomes Through Cultural Competence Training for Physicians
University of Michigan
NCT01251523
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
Teva Branded Pharmaceutical Products R&D
NCT02031640
A Reminder System for Paper-Based Asthma Guidelines in the Pediatric Emergency Department
Vanderbilt University Medical Center
NCT00699439
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
Brigham and Women's Hospital
NCT01290874
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
AstraZeneca
NCT03347279
Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN
Wake Forest University Health Sciences
NCT01280500
An Electronic Decision Support Tool to Improve Outpatient Asthma Care
Agency for Healthcare Research and Quality (AHRQ)
NCT01522144
Outdoor Allergen Exposure, Sensitivity, and Acute Asthma
National Institute of Environmental Health Sciences (NIEHS)
NCT00043992
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
Sanofi
NCT00044824
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
MedImmune
NCT01238861
Asthma in the Delta Region of Arkansas (ADRA): Prevalence and Morbidity
Arkansas Children's Hospital Research Institute
NCT00589719
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
AstraZeneca
NCT00317044
Stress, Environment, and Genetics in Urban Children With Asthma
Brigham and Women's Hospital
NCT00269256
Asthma Digital Study
Elevance Health
NCT04609644
Role of TLR4 in Environmental Asthma
John Sundy
NCT00671892
Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler
Teva Branded Pharmaceutical Products R&D
NCT02980133
A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
Hoffmann-La Roche
NCT01922037
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
Novartis Pharmaceuticals
NCT00529529
Asthma and Obstructive Sleep Apnea (OSA)
University of Wisconsin, Madison
NCT01026298
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
AstraZeneca
NCT03170271
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.
GlaxoSmithKline
NCT00398645
12-Week Study in Adult Subjects With Asthma
Dey
NCT01516073
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
Teva Branded Pharmaceutical Products R&D
NCT02040766
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
Novartis Pharmaceuticals
NCT00079937
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.
GlaxoSmithKline
NCT00603746
Online Asthma Self-Management for Children Aged 5-10 and Their Parents
Oregon Center for Applied Science
NCT02602392
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma
GlaxoSmithKline
NCT00452699
Study Of Patients With Allergic Rhinitis And Asthma
GlaxoSmithKline
NCT00296530
Genetic Risk Factors for Severe Asthma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00090740
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
MedImmune
NCT02054130
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 27 |
| Phase 2 | 81 |
| Phase 3 | 51 |
| Phase 4 | 38 |
Top Sponsors
Named interventions
Most-linked intervention names on Asthma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Asthma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Asthma page
378 registered trials, 70 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 70 Asthma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Asthma trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Asthma condition card totals 378 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.